Aprea Therapeutics
APRE
50 hedge funds and large institutions have $31.4M invested in Aprea Therapeutics in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 21 reducing their positions, and 26 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.56% less ownership
Funds ownership: 2.11% → 1.54% (-0.56%)
2% less call options, than puts
Call options by funds: $705K | Put options by funds: $723K
25% less funds holding
Funds holding: 67 → 50 (-17)
30% less capital invested
Capital invested by funds: $44.8M → $31.4M (-$13.4M)
62% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 21
65% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.39M |
| 2 |
PP
PDT Partners
New York
|
+$574K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$338K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$242K |
| 5 |
JP Morgan Chase
New York
|
+$202K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
5VM
5AM Venture Management
San Francisco,
California
|
-$3.16M |
| 2 |
BlackRock
New York
|
-$2.09M |
| 3 |
Two Sigma Advisers
New York
|
-$1.73M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.71M |
| 5 |
Two Sigma Investments
New York
|
-$1.65M |
APRE Hedge Fund Activity: Q2 2021 in Review
50 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q2 2021, worth a combined $31.4M — down 30% from $44.8M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of APRE and 9 opened new positions — a net loss of 17 holders — while 21 trimmed existing stakes and 8 added.
The largest buyer was Kennedy Capital Management, adding an estimated $1.39M. The largest seller was 5AM Venture Management, exiting entirely with an estimated $3.16M sold.
- 50 institutional investors held Aprea Therapeutics (APRE) as of Q2 2021, down from 67 in Q1 2021.
- Funds reported $31.4M of Aprea Therapeutics stock for Q2 2021, down 30% quarter-over-quarter.
- 9 funds opened new Aprea Therapeutics positions in Q2 2021 and 26 closed out, a net change of -17 holders.
- The largest Aprea Therapeutics buyer in Q2 2021 was Kennedy Capital Management, an estimated $1.39M added.
- The largest Aprea Therapeutics seller in Q2 2021 was 5AM Venture Management, an estimated $3.16M sold.
Based on aggregated 13F filings for Q2 2021.